Literature DB >> 22564988

Quantitative DNA methylation analysis identifies a single CpG dinucleotide important for ZAP-70 expression and predictive of prognosis in chronic lymphocytic leukemia.

Rainer Claus1, David M Lucas, Stephan Stilgenbauer, Amy S Ruppert, Lianbo Yu, Manuela Zucknick, Daniel Mertens, Andreas Bühler, Christopher C Oakes, Richard A Larson, Neil E Kay, Diane F Jelinek, Thomas J Kipps, Laura Z Rassenti, John G Gribben, Hartmut Döhner, Nyla A Heerema, Guido Marcucci, Christoph Plass, John C Byrd.   

Abstract

PURPOSE: Increased ZAP-70 expression predicts poor prognosis in chronic lymphocytic leukemia (CLL). Current methods for accurately measuring ZAP-70 expression are problematic, preventing widespread application of these tests in clinical decision making. We therefore used comprehensive DNA methylation profiling of the ZAP-70 regulatory region to identify sites important for transcriptional control. PATIENTS AND METHODS: High-resolution quantitative DNA methylation analysis of the entire ZAP-70 gene regulatory regions was conducted on 247 samples from patients with CLL from four independent clinical studies.
RESULTS: Through this comprehensive analysis, we identified a small area in the 5' regulatory region of ZAP-70 that showed large variability in methylation in CLL samples but was universally methylated in normal B cells. High correlation with mRNA and protein expression, as well as activity in promoter reporter assays, revealed that within this differentially methylated region, a single CpG dinucleotide and neighboring nucleotides are particularly important in ZAP-70 transcriptional regulation. Furthermore, by using clustering approaches, we identified a prognostic role for this site in four independent data sets of patients with CLL using time to treatment, progression-free survival, and overall survival as clinical end points.
CONCLUSION: Comprehensive quantitative DNA methylation analysis of the ZAP-70 gene in CLL identified important regions responsible for transcriptional regulation. In addition, loss of methylation at a specific single CpG dinucleotide in the ZAP-70 5' regulatory sequence is a highly predictive and reproducible biomarker of poor prognosis in this disease. This work demonstrates the feasibility of using quantitative specific ZAP-70 methylation analysis as a relevant clinically applicable prognostic test in CLL.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22564988      PMCID: PMC3397783          DOI: 10.1200/JCO.2011.39.3090

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Analysis and quantification of multiple methylation variable positions in CpG islands by Pyrosequencing.

Authors:  Jörg Tost; Jenny Dunker; Ivo Glynne Gut
Journal:  Biotechniques       Date:  2003-07       Impact factor: 1.993

2.  ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia.

Authors:  Laura Z Rassenti; Lang Huynh; Tracy L Toy; Liguang Chen; Michael J Keating; John G Gribben; Donna S Neuberg; Ian W Flinn; Kanti R Rai; John C Byrd; Neil E Kay; Andrew Greaves; Arthur Weiss; Thomas J Kipps
Journal:  N Engl J Med       Date:  2004-08-26       Impact factor: 91.245

3.  ZAP-70 directly enhances IgM signaling in chronic lymphocytic leukemia.

Authors:  Liguang Chen; John Apgar; Lang Huynh; Frank Dicker; Teresa Giago-McGahan; Laura Rassenti; Arthur Weiss; Thomas J Kipps
Journal:  Blood       Date:  2004-10-28       Impact factor: 22.113

4.  Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia.

Authors:  R N Damle; T Wasil; F Fais; F Ghiotto; A Valetto; S L Allen; A Buchbinder; D Budman; K Dittmar; J Kolitz; S M Lichtman; P Schulman; V P Vinciguerra; K R Rai; M Ferrarini; N Chiorazzi
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

5.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia.

Authors:  T J Hamblin; Z Davis; A Gardiner; D G Oscier; F K Stevenson
Journal:  Blood       Date:  1999-09-15       Impact factor: 22.113

6.  Chemoimmunotherapy with fludarabine and rituximab produces extended overall survival and progression-free survival in chronic lymphocytic leukemia: long-term follow-up of CALGB study 9712.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Bercedis L Peterson; John G Gribben; Vicki A Morrison; Kanti R Rai; Richard A Larson; John C Byrd
Journal:  J Clin Oncol       Date:  2011-02-14       Impact factor: 44.544

7.  ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia.

Authors:  Marta Crespo; Francesc Bosch; Neus Villamor; Beatriz Bellosillo; Dolors Colomer; María Rozman; Silvia Marcé; Armando López-Guillermo; Elies Campo; Emili Montserrat
Journal:  N Engl J Med       Date:  2003-05-01       Impact factor: 91.245

8.  Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors.

Authors:  F Fais; F Ghiotto; S Hashimoto; B Sellars; A Valetto; S L Allen; P Schulman; V P Vinciguerra; K Rai; L Z Rassenti; T J Kipps; G Dighiero; H W Schroeder; M Ferrarini; N Chiorazzi
Journal:  J Clin Invest       Date:  1998-10-15       Impact factor: 14.808

9.  Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from Cancer and Leukemia Group B 9712 (CALGB 9712).

Authors:  John C Byrd; Bercedis L Peterson; Vicki A Morrison; Kathleen Park; Robert Jacobson; Eva Hoke; James W Vardiman; Kanti Rai; Charles A Schiffer; Richard A Larson
Journal:  Blood       Date:  2002-07-05       Impact factor: 22.113

10.  Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia.

Authors:  A Rosenwald; A A Alizadeh; G Widhopf; R Simon; R E Davis; X Yu; L Yang; O K Pickeral; L Z Rassenti; J Powell; D Botstein; J C Byrd; M R Grever; B D Cheson; N Chiorazzi; W H Wilson; T J Kipps; P O Brown; L M Staudt
Journal:  J Exp Med       Date:  2001-12-03       Impact factor: 14.307

View more
  55 in total

1.  Cytogenetic prioritization with inclusion of molecular markers predicts outcome in previously untreated patients with chronic lymphocytic leukemia treated with fludarabine or fludarabine plus cyclophosphamide: a long-term follow-up study of the US intergroup phase III trial E2997.

Authors:  David M Lucas; Amy S Ruppert; Gerard Lozanski; Gordon W Dewald; Arletta Lozanski; Rainer Claus; Christoph Plass; Ian W Flinn; Donna S Neuberg; Elisabeth M Paietta; John M Bennett; Diane F Jelinek; John G Gribben; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman; John C Byrd; Michael R Grever
Journal:  Leuk Lymphoma       Date:  2015-03-30

2.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

Review 3.  Mechanisms of epigenetic deregulation in lymphoid neoplasms.

Authors:  Yanwen Jiang; Katerina Hatzi; Rita Shaknovich
Journal:  Blood       Date:  2013-05-23       Impact factor: 22.113

4.  TCL1 targeting miR-3676 is codeleted with tumor protein p53 in chronic lymphocytic leukemia.

Authors:  Veronica Balatti; Lara Rizzotto; Cecelia Miller; Alexey Palamarchuk; Paolo Fadda; Rosantony Pandolfo; Laura Z Rassenti; Erin Hertlein; Amy S Ruppert; Arletta Lozanski; Gerard Lozanski; Thomas J Kipps; John C Byrd; Carlo M Croce; Yuri Pekarsky
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-02       Impact factor: 11.205

5.  Type 3 iodothyronine deiodinase in neonatal goats: molecular cloning, expression, localization, and methylation signature.

Authors:  Tao Zhong; Peng-Fei Jin; Wei Zhao; Lin-Jie Wang; Li Li; Hong-Ping Zhang
Journal:  Funct Integr Genomics       Date:  2016-04-23       Impact factor: 3.410

6.  Genome-wide DNA methylation in neonates exposed to maternal depression, anxiety, or SSRI medication during pregnancy.

Authors:  Amy L Non; Alexandra M Binder; Laura D Kubzansky; Karin B Michels
Journal:  Epigenetics       Date:  2014-04-21       Impact factor: 4.528

Review 7.  Molecular pathogenesis of CLL and its evolution.

Authors:  David Rodríguez; Gabriel Bretones; Javier R Arango; Víctor Valdespino; Elías Campo; Víctor Quesada; Carlos López-Otín
Journal:  Int J Hematol       Date:  2015-01-29       Impact factor: 2.490

Review 8.  Molecular basis of chronic lymphocytic leukemia diagnosis and prognosis.

Authors:  Mohammad Shahjahani; Javad Mohammadiasl; Fatemeh Noroozi; Mohammad Seghatoleslami; Saeid Shahrabi; Fakhredin Saba; Najmaldin Saki
Journal:  Cell Oncol (Dordr)       Date:  2015-01-07       Impact factor: 6.730

Review 9.  Uncovering the DNA methylome in chronic lymphocytic leukemia.

Authors:  Nicola Cahill; Richard Rosenquist
Journal:  Epigenetics       Date:  2013-01-15       Impact factor: 4.528

10.  PrEMeR-CG: inferring nucleotide level DNA methylation values from MethylCap-seq data.

Authors:  David E Frankhouser; Mark Murphy; James S Blachly; Jincheol Park; Mike W Zoller; Javkhlan-Ochir Ganbat; John Curfman; John C Byrd; Shili Lin; Guido Marcucci; Pearlly Yan; Ralf Bundschuh
Journal:  Bioinformatics       Date:  2014-08-31       Impact factor: 6.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.